secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evolus, Inc. (EOLS)
CIK:        0001570562
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001570562-22-000141
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evolus Q3 revenue +27% to $33.9M; reiterates FY2022 guidance at top end
-----------------------------------------------------------------------

- Revenue $33.9M (+27% YoY); deferred $3.5M incremental due to 'Switch Your Tox' campaign, understating growth.
- FY2022 revenue guidance top end $143-150M; non-GAAP opex guidance lowered to lower half of $135-140M.
- Cash $65.6M; expects to fund through breakeven; operating cash use $17.1M, $3.8M less than Q2.
- Added 650 new accounts (total >8,800); Evolus Rewards ~450,000 members with record 100,000 redemptions.
- Launched Great Britain ops for Nuceiva; Phase II extra-strength Jeuveau enrollment completed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1570562/000157056222000141/0001570562-22-000141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1570562/000157056222000141/eols-20221108.htm
  HTML page:      https://secwatch.observer/filing/0001570562-22-000141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer